Rosetta Genomics Ltd. (NASDAQ:ROSG) Major Shareholder Healthcare Master Fund Sabby Buys 175,828 Shares

Rosetta Genomics Ltd. (NASDAQ:ROSG) major shareholder Healthcare Master Fund Sabby bought 175,828 shares of Rosetta Genomics stock in a transaction dated Tuesday, March 13th. The stock was acquired at an average cost of $0.42 per share, with a total value of $73,847.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Healthcare Master Fund Sabby also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Thursday, March 15th, Healthcare Master Fund Sabby acquired 119,761 shares of Rosetta Genomics stock. The shares were purchased at an average cost of $0.42 per share, with a total value of $50,299.62.

NASDAQ ROSG remained flat at $$0.40 on Friday. The company’s stock had a trading volume of 8,450 shares, compared to its average volume of 69,939. Rosetta Genomics Ltd. has a 1-year low of $0.23 and a 1-year high of $3.29. The company has a market capitalization of $2.40, a price-to-earnings ratio of -0.04 and a beta of 0.47.

Several equities analysts have weighed in on the company. Barrington Research lowered Rosetta Genomics from an “outperform” rating to a “market perform” rating in a report on Monday, December 18th. ValuEngine raised Rosetta Genomics from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd.

TRADEMARK VIOLATION WARNING: This story was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/04/07/healthcare-master-fund-sabby-purchases-175828-shares-of-rosetta-genomics-ltd-rosg-stock.html.

Rosetta Genomics Company Profile

Rosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests-based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH).

Receive News & Ratings for Rosetta Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rosetta Genomics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply